RevolKa, a Tokyo, Japan-based biotech company providing a cutting-edge AI-driven protein engineering technology platform, has secured 100 million JPY (US$0.7M) in financing, bringing its total Series A extension funding to 250 million JPY (US$1.7M).
Investors
The funding round was led by D3 LLC and DEEPCORE Inc.
D3 LLC, established in 2017, is committed to advancing global healthcare through the funding and development of innovative scientific and technological ideas. They support entrepreneurs at every stage, from discovery to market deployment.
DEEPCORE Inc. focuses on AI and advanced technologies, investing in early-stage startups across various sectors. They also provide additional support through their "KERNEL" community and accelerator programs, helping startups grow and expand internationally.
RevolKa Use of Funds
The new funding will accelerate RevolKa’s drug discovery efforts.
About RevolKa
Founded in April 2021, RevolKa is a biotechnology company with a mission to create novel proteins useful for therapeutics and industries using their proprietary technology, aiProtein, an AI-assisted directed evolution of proteins. It uses AI to engineer high-performance proteins, surpassing natural evolution and fostering successful collaborations with industry partners. The company is located in Tokyo, Japan with laboratories located in Sendai.
Funding Details
Company: RevolKa Ltd.
Raised: $1.7M
Round: Series A Extension
Funding Date: August 2024
Lead Investors: D3 LLC, DEEPCORE Inc.
Additional Investors:
Company Website: https://www.revolka.com/
Software Category: Drug Discovery
Source: https://www.businesswire.com/news/home/20240829233717/en/